Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years
By LabMedica International staff writers Posted on 17 Jul 2020 |
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)
Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer for the detection of syphilis.
Awareness is an international IVD company that develops, manufactures, and markets high quality in-vitro diagnostic instrumentation, and diagnostic test kits. The company’s instrument portfolio includes biochemistry, ELISA, chemiluminescence, imaging analytics, electrolyte instruments, and supportive equipment. Awareness’ diagnostic test kit portfolio includes ELISA kits with a focus on autoimmune and infectious disease testing, biochemistry test kits, and allergy screening kits, which support over 200 specific allergens.
Laboratories can now automate nontreponemal testing and drive significant operational efficiencies while minimizing false-positive results with Awareness’ ChemWell RPR automated nontreponemal analyzer for the detection of syphilis. Designed to work with carbon antigen, the RPR analyzer uses four standard 48 well microwell plates instead of manual RPR cards to analyze up to 192 samples per hour without any user intervention. It utilizes a high resolution imaging system which captures the reaction taking place in each of the back-lit wells that are interpreted by a proven algorithm and provide an accurate and reliable negative or positive result based on the captured images. It can perform visual identification of positive or negative reaction with a sensitivity of 98.8% and a specificity of 99.8%.
An additional test can be run on positive samples to determine titers up to 1:2048 dilution for therapeutic monitoring. The software is included with the user-friendly system at no additional cost and features an intuitive interface that allows for easy navigation and use. Automated features such as fluid handling, mixing, timing, image capture, image processing, and reporting are all handled by the software.
Awareness is an international IVD company that develops, manufactures, and markets high quality in-vitro diagnostic instrumentation, and diagnostic test kits. The company’s instrument portfolio includes biochemistry, ELISA, chemiluminescence, imaging analytics, electrolyte instruments, and supportive equipment. Awareness’ diagnostic test kit portfolio includes ELISA kits with a focus on autoimmune and infectious disease testing, biochemistry test kits, and allergy screening kits, which support over 200 specific allergens.
Laboratories can now automate nontreponemal testing and drive significant operational efficiencies while minimizing false-positive results with Awareness’ ChemWell RPR automated nontreponemal analyzer for the detection of syphilis. Designed to work with carbon antigen, the RPR analyzer uses four standard 48 well microwell plates instead of manual RPR cards to analyze up to 192 samples per hour without any user intervention. It utilizes a high resolution imaging system which captures the reaction taking place in each of the back-lit wells that are interpreted by a proven algorithm and provide an accurate and reliable negative or positive result based on the captured images. It can perform visual identification of positive or negative reaction with a sensitivity of 98.8% and a specificity of 99.8%.
An additional test can be run on positive samples to determine titers up to 1:2048 dilution for therapeutic monitoring. The software is included with the user-friendly system at no additional cost and features an intuitive interface that allows for easy navigation and use. Automated features such as fluid handling, mixing, timing, image capture, image processing, and reporting are all handled by the software.
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus